Ruffin R E, Wolff R K, Dolovich M B, Rossman C M, Fitzgerald J D, Newhouse M T
Chest. 1978 Apr;73(4):501-6. doi: 10.1378/chest.73.4.501.
The anticholinergic bronchodilator drug, Sch 1000, was administered as an aerosol by a metered-dose inhaler (200 microgram) to six normal and six bronchitic subjects. The short-term effect on mucociliary clearance was assessed and compared to a placebo (propellant and dispersal agent) in a double-blind crossover study. Mucociliary clearance in the normal group was significantly faster with administration of Sch 1000 than with placebo (P less than 0.01). There was no significant difference between the effects of administration of Sch 1000 and placebo on mucociliary clearance in the bronchitic group. Pulmonary function was significantly increased by therapy with Sch 1000 (as compared to administration of placebo) in the bronchitic group for two hours (P less than 0.05) and in the normal group for one hour (P less than 0.05). In another study, 12 normal subjects inhaled aerosols containing 40 microgram of placebo or 400 microgram of Sch 1000 from metered-dose inhalers on separate days in a randomized double-blind fashion. A significant sustained improvement in pulmonary function (P less than 0.05) and a transient fall in diastolic blood pressure were observed after administration of Sch 1000.
抗胆碱能支气管扩张药Sch 1000通过定量吸入器以气雾剂形式（200微克）给予6名正常受试者和6名支气管炎患者。在一项双盲交叉研究中，评估了其对黏液纤毛清除功能的短期影响，并与安慰剂（推进剂和分散剂）进行了比较。正常组中，给予Sch 1000时黏液纤毛清除速度显著快于给予安慰剂时（P<0.01）。在支气管炎组中，给予Sch 1000和安慰剂对黏液纤毛清除功能的影响无显著差异。在支气管炎组中，Sch 1000治疗（与给予安慰剂相比）使肺功能显著提高两小时（P<0.05），在正常组中提高一小时（P<0.05）。在另一项研究中，12名正常受试者以随机双盲方式在不同日期从定量吸入器吸入含40微克安慰剂或400微克Sch 1000的气雾剂。给予Sch 1000后，观察到肺功能有显著持续改善（P<0.05），舒张压有短暂下降。
